Current Psychiatry Reports

, Volume 12, Issue 2, pp 111–115 | Cite as

Peripheral Vasculopathy Associated with Psychostimulant Treatment in Children with Attention-Deficit/Hyperactivity Disorder

  • Zheya Jenny Yu
  • Caroline Parker-Kotler
  • Kathleen Tran
  • Ronald A. Weller
  • Elizabeth B. Weller
Article

Abstract

Psychostimulants (methylphenidate and amphetamine salt) are the pharmacologic treatment of choice for children with attention-deficit/hyperactivity disorder. However, psychostimulants have been linked to a variety of vascular problems, including peripheral vasculopathy. This article describes four boys with attention-deficit/hyperactivity disorder who developed vasculopathy during treatment with psychostimulants.

Keywords

Psychostimulants Vasculopathy 

Notes

Disclosure

Drs. Ronald and Elizabeth Weller are co-owners of the Children’s Interview for Psychiatric Syndromes (and the parent’s version) and have received annual royalties from copyright ownership of this diagnostic interview. Dr. Elizabeth Weller was the principal investigator for a grant from GlaxoSmithKline to investigate the tolerability and efficacy of lamotrigine in children and adolescents diagnosed with bipolar disorder. No other potential conflicts of interest relevant to this article were reported.

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.
    Guevara J, Lozano P, Wickizer T, et al.: Psychotropic medication use in a population of children who have attention-deficit/hyperactivity disorder. Pediatrics 2002, 109:733–739.CrossRefPubMedGoogle Scholar
  2. 2.
    Sadeghian H: Lacunar stroke associated with methylphenidate abuse. Can J Neurol Sci 2004, 31:109–111.PubMedGoogle Scholar
  3. 3.
    Thai DL, Yurasists LN, Rudolph GR, et al.: Comparative pharmacokinetics and tissue distribution of the d-enantiomers of para-substituted methylphenidate analogs. Drug Metab Dispos 1999, 27:645–650.PubMedGoogle Scholar
  4. 4.
    Stahl SM: Essential psychopharmacology, neuroscientific basis and practical applications. In Cognitive Enhancers, edn 2. Edited by Stahl SM. Cambridge, United Kingdom: Cambridge University Press; 2004:461–466.Google Scholar
  5. 5.
    Dulcan MK, Lizarralde C: Helping parents, youth, and teachers understand medications for behavioral and emotional problems: a resource book of medication information handouts. In Stimulants, edn 2. Edited by Dulcan MK, Lizarralde C. Washington, DC: American Psychiatric Publishing; 2003:75–80.Google Scholar
  6. 6.
    Kokkinos J, Levine SR: Possible association of ischemic stroke with phentamine. Stroke 1993, 24:310–313.PubMedGoogle Scholar
  7. 7.
    Jefferson HJ, Jayne DR: Peripheral vasculopathy and nephropathy in association with phentermine. Nephrol Dial Transplant 1999, 14:1761–1763.CrossRefPubMedGoogle Scholar
  8. 8.
    Leithauser B, Langheinrich AC, Rau WS, et al.: A 22-year-old woman with lower limb arteriopathy. Buerger’s disease, or methamphentamine- or cannabis-induced arteritis? Heart Vessels 2005, 20:39–43.CrossRefPubMedGoogle Scholar
  9. 9.
    Bingham C, Beaman M, Nicholls AJ, Anthony PP: Necrotizing renal vasculopathy resulting in chronic renal failure after ingestion of methamphetamine and 3,4-methylenedioxymethamphetamine (‘ecstasy’). Nephrol Dial Transplant 1998, 13:2654–2655.CrossRefPubMedGoogle Scholar
  10. 10.
    •• Syed R, Moore T: Methylphenidate and dextroamphetamine-induced peripheral vasculopathy. J Clin Rheumatol 2008, 14:30–33. This was a case report of four patients treated with MPH (n = 2) or dextroamphetamine (n = 2) presenting with acral cyanosis, livedo reticularis, or RS potentially contributing to vasculopathy.Google Scholar
  11. 11.
    •• Goldman W, Seltzer R, Reuman P: Association between treatment with central nervous system stimulants and Raynaud’s syndrome in children. Arthritis Rheum 2008, 58:563–566. This was a retrospective case-control study of pediatric rheumatology patients (with and without RS) that examined the association between development of RS and CNS stimulants used to treat ADHD.Google Scholar
  12. 12.
    Sule SD, Wigley FM: Current rheumatology: diagnosis and treatment. In Raynaud Phenomenon. Edited by Imboden J, Hellmann DB, Stone JH. Columbus, OH: McGraw-Hill; 2004:183–185.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Zheya Jenny Yu
    • 1
  • Caroline Parker-Kotler
    • 2
  • Kathleen Tran
    • 3
  • Ronald A. Weller
    • 4
  • Elizabeth B. Weller
    • 5
  1. 1.Hall-Mercer MH/MR Center, Pennsylvania HospitalUniversity of Pennsylvania Health SystemPhiladelphiaUSA
  2. 2.Greentree PediatricsMarltonUSA
  3. 3.Department of MedicineMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  4. 4.Department of PsychiatryUniversity of PennsylvaniaPhiladelphiaUSA
  5. 5.The Children’s Hospital of PhiladelphiaUniversity of PennsylvaniaPhiladelphiaUSA

Personalised recommendations